These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37799963)

  • 1. Redefining the polypill: pros and cons in cardiovascular precision medicine.
    Birla S; Angural A; Madathumchalil A; Shende RV; Shastry SV; Mahadevappa M; Shambhu SK; Vishwanath P; Prashant A
    Front Pharmacol; 2023; 14():1268119. PubMed ID: 37799963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
    Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
    J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis.
    Salim H; Musmar B; Saifi M; Ayyad M; Ruzieh M; Azar J; Nazzal Z
    Curr Cardiol Rev; 2024; 20(2):61-71. PubMed ID: 38265377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.
    Memon RA; Raveena Bai B; Simran F; Kumari M; Aisha F; Sai Kiran K; Kakarlapudi Y; Saleem F
    Cureus; 2023 Jan; 15(1):e34134. PubMed ID: 36843692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
    Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
    Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of different cardiovascular risk factors with a combination tablet (polypill)].
    Bramlage P; März W; Westermann D; Weisser B; Wirtz JH; Zeymer U; Baumgart P; van Mark G; Laufs U; Krämer BK; Unger T
    Herz; 2018 May; 43(3):246-257. PubMed ID: 28341983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset.
    Webster R; Bullen C; Patel A; Selak V; Stepien S; Thom S; Rodgers A
    Int J Cardiol; 2017 Dec; 249():443-447. PubMed ID: 28986058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.
    Webster R; Rodgers A
    Curr Cardiol Rep; 2015 Dec; 17(12):121. PubMed ID: 26497041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polypill Variants (Quarter Pill Trials).
    Teo K; Yusuf S
    Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polypill treatments for cardiovascular diseases.
    Webster R; Rodgers A
    Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.
    Liu H; Massi L; Laba TL; Peiris D; Usherwood T; Patel A; Cass A; Eades AM; Redfern J; Hayman N; Howard K; Brien JA; Jan S
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):301-8. PubMed ID: 25944629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.